Optimization of post-insertion method to conjugate Doxil with anti-CD133 monoclonal antibodies: Investigating the specific binding and cytotoxicity to colorectal cancer cells in vitro

Noshahr, Karim Dadashi; Shamsi, Fahimeh; Valtchev, Peter; Kokhaei, Parviz; Hemati, Maral; Eidgahi, Mohammad Reza Akbari; Khaleghian, Ali

doi:10.1016/j.jsps.2020.09.003

Cited by 13 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 39 articles included in this review, 14 analyzed the antitumor effect of lipid nanocarriers in CRC ( Table 1 ), including liposomes coated with PEG chains (11 articles), the chemotherapeutic drug Doxil ® (2 articles), and a cerasome (1 article). Of note, studies with Doxil ® targeted against CD133 + 34 and CD44 + tumor cells 42 -both of which are clusters of differentiation associated with…”

Section: Resultsmentioning

confidence: 99%

“…For example, a recent study used functionalized DCLK1 folic acid conjugated hesperetin encapsulated in chitosan NPs to selectively target colorectal CSC. 33 The stem cell biomarker CD133 has become a way of targeting colon, 34 breast 35 and ovarian stem cells, 36 among others. Recently, this ligand has been used by Mohd-Zahid et al to synthesize PEGylated gold NPs that significantly increased intracellular drug (5-FU) accumulation in HCT116 CRC cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review

Cepero¹,

Luque²,

Cabeza³

et al. 2022

IJN

View full text Add to dashboard Cite

The failure of chemotherapeutic treatment in colorectal cancer (CRC), the second most mortal cancer worldwide, is associated with several drug limitations, such as non-selective distribution, short half-life, and development of multiple resistances. One of the most promising strategies in CRC therapy is the development of delivery systems based on nanomaterials that can transport antitumor agents to the tumor site more efficiently, increasing accumulation within the tumor and thus the antitumor effect. In addition to taking advantage of the increased permeability and retention effect (EPR) of solid tumors, these nanoformulations can be conjugated with monoclonal antibodies that recognize molecular markers that are specifically over-expressed on CRC cells. Active targeting of nanoformulations reduces the adverse effects associated with the cytotoxic activity of drugs in healthy tissues, which will be of interest for improving the quality of life of cancer patients in the future. This review focuses on in vitro and in vivo studies of drug delivery nanoformulations functionalized with monoclonal antibodies for targeted therapy of CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review

Cepero¹,

Luque²,

Cabeza³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…Regarding colon cancer treatment, researchers proved the feasibility of coupling Doxil ® with anti-CD44 mAb [ 90 ] and anti-CD133 mAb [ 91 ] and accomplished higher therapeutic efficacy compared to other treatments (non-targeted Doxil ® and free DOX) against CD44-positive C-26 cells (in vitro and in vivo) and CD133-positive HT-29 cells, respectively. Based on preliminary findings [ 92 ], the progression of metastatic colorectal cancer could be haltered by 5-FU-loaded liposomes covalently linked to an antibody against the Frizzled 10 protein.…”

Section: Antibody-functionalized Lipid Nanoparticles For Anticancer D...mentioning

confidence: 99%

Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy

et al. 2023

View full text Add to dashboard Cite

Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles—solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid–polymer hybrid nanoparticles—have received particular interest in anticancer drug delivery to solid tumors. To improve selectivity for target cells and, thus, therapeutic efficacy, lipid nanoparticles have been functionalized with antibodies that bind to receptors overexpressed in angiogenic endothelial cells or cancer cells. Most papers dealing with the preclinical results of antibody-conjugated nanoparticles claim low systemic toxicity and effective tumor inhibition, which have not been successfully translated into clinical use yet. This review aims to summarize the current “state-of-the-art” in anticancer drug delivery using antibody-functionalized lipid-based nanoparticles. It includes an update on promising candidates that entered clinical trials and some explanations for low translation success.

show abstract

“…Further investigation is required before Nbs can be administered regularly. Besides avoiding toxicity, ongoing work with Nbs strives to optimize the size, drug leakage, and release pattern of conjugated mAbs in an effort to improve efficacy [94].…”

Section: Nanobodiesmentioning

confidence: 99%

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers

Carlsen¹,

Huntington²,

El‐Deiry³

2021

Preprint

View full text Add to dashboard Cite

Though early-stage colorectal cancer has a high 5-year survival rate of 65-92% depending on the specific stage, this probability drops to 13% after the cancer metastasizes. Frontline treatments for colorectal cancer such as chemotherapy and radiation often produce dose-limiting toxicities in patients and acquired resistance in cancer cells. Additional targeted treatments are needed to improve patient outcomes and quality of life. Immunotherapy involves treatment with peptides, cells, antibodies, viruses, or small molecules to engage or train the immune system to kill cancer cells. Preclinical and clinical investigations of immunotherapy for treatment of colorectal cancer including immune checkpoint blockade, adoptive cell therapy, monoclonal antibodies, oncolytic viruses, anti-cancer vaccines, and immune system modulators have been promising, but demonstrate limitations for patients with proficient mismatch repair enzymes. In this review, we discuss preclinical and clinical studies investigating immunotherapy for treatment of colorectal cancer and predictive biomarkers for response to these treatments. We also consider open questions including optimal combination treatments to maximize efficacy, minimize toxicity, and prevent acquired resistance and approaches to sensitize mismatch repair proficient patients to immunotherapy.

show abstract

Optimization of post-insertion method to conjugate Doxil with anti-CD133 monoclonal antibodies: Investigating the specific binding and cytotoxicity to colorectal cancer cells in vitro

Cited by 13 publications

References 30 publications

Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review

Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review

Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers

Contact Info

Product

Resources

About